T-3011

N/A

Report date: 2024/04/16 17:47:52

Base Information

Drug NameT-3011
Drug Alias NameT3011疱疹病毒（深圳市亦诺微医药）MVR-T3011T3011MVR-T3011 ITMVR-T3011 IV +[8] 
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionProgrammed cell death protein 1 blockersInterleukin-12 stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects +[5] 
TargetsInterleukin-12Programmed cell death protein 1
Therapy Area/IndicationsSolid tumoursAscitesUrinary Bladder Neoplasms +[21] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesImmvira Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImmvira Pharma Co LtdSuzhou Yinuo micro Medical Technology Co LtdFudan University +[7] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursAscitesUrinary Bladder Neoplasms +[20] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A